Skip to content

Use of CEST (Chemical Exchange Saturation Transfer) Imaging in PET/MRI

Use of CEST (Chemical Exchange Saturation Transfer) Imaging in PET/MRI

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05464992
Acronym
GlioCEST
Enrollment
800
Registered
2022-07-19
Start date
2022-12-28
Completion date
2036-12-28
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain Metastases, Glioma

Brief summary

Standard Magnetic Resonance Imaging (MRI) is based on the excitation of hydrogen nuclei that are presents in water molecules, which abundance in human body allows for obtention of superior contrast. However, assessing the presence of other molecules than water in tissues is also of great clinical interest to probe metabolites related to physiological body function and pathological conditions. Chemical exchange saturation transfer (CEST) allow to overcome some limitations of proton magnetic resonance spectroscopy (1H-MRS) by exploiting chemical properties of the targeted molecule through a continuous process of re-saturation and exchange, and thus detecting it with increased sensitivity, from two orders of magnitude. Moreover, CEST technique is based on imaging sequences and can therefore benefit from well-known fast acquisition strategies, as well as improved spatial resolution.

Detailed description

For this study the investigators propose to include an additional CEST sequence in standard PET/MRI exam in order to obtain a cartography with biochemical informations from tissues in patients with glioma or brain metastases.

Interventions

OTHERAdditional CEST sequences during PET/MRI exam

CE-Marked Advanced Technology Software Modules (ATSM) for Magnetic Resonance Imaging from General Electric Healthcare

Sponsors

Centre Paul Strauss
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Patients admitted to the Nuclear Medicine and Molecular Imaging department of ICANS (Institut de cancérologie strasbourg Europe) for a PET/MRI exam dedicated to: * Preoperative evaluation of a cerebral expansion lesion * Evaluation of glioma recurrences * Evaluation of brain metastases * Evaluation of recurrence of metastases

Exclusion criteria

* Contraindication to the realization of an MRI * Minor or patients placed under guardianship or supervision * Patients deprived of liberty * Patients placed under judicial protection * Patients that are not able to express their consent * Pregnant and breastfeeding women

Design outcomes

Primary

MeasureTime frameDescription
Obtention, from a set of brain PET-MRI images, of an intratissular pH mapping in patients with glioma or brain metastasesthrough study completion, up to 14 yearsEvaluation at the cerebral level on the acquisition images of residual volume in MRI

Secondary

MeasureTime frame
Correlate intratissular pH mapping and location of recurrencethrough study follow-up, up to 10 years
Correlate average pH of the tumor and histopathologythrough study follow-up, up to 10 years
Correlate average pH of the tumor and Disease-Free Survival (DFS)through study follow-up, up to 10 years
Correlate average pH of the tumor and Overall survival (OS)through study follow-up, up to 10 years

Countries

France

Contacts

CONTACTManon VOEGELIN
promotion-rc@icans.eu(0)368339523
CONTACTClaire VIT
promotion-rc@icans.eu(0)368339523

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026